Gordafaried Deyanat‐Yazdi
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Glycosylation and Glycoproteins Research, RNA Research and Splicing, Cancer therapeutics and mechanisms, Crystallization and Solubility Studies
Most-Cited Works
- → Structure−Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor(2005)235 cited
- → Synthesis and Structure–Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure(2011)105 cited
- → Salinosporamides D−J from the Marine Actinomycete Salinispora tropica, Bromosalinosporamide, and Thioester Derivatives Are Potent Inhibitors of the 20S Proteasome(2007)87 cited
- → The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen(2017)59 cited
- → Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint(2018)35 cited
- → Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth(2009)32 cited
- → Tubulin Photoaffinity Labeling with Biotin‐Tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents(2008)17 cited
- → PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation – therapeutic implications for autoimmunity(2024)8 cited
- Abstract #5236: Lenalidomide affects F-Actin cytoskeleton in mantle cell lymphoma cells in vitro(2009)
- Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib)(2006)